HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention

2014362 citationsJournal Articlehybrid Open Access

Authors

Deborah Donnell · Fred Hutch Cancer Center

Jared M. Baeten · University of Washington

Namandjé N. Bumpus · Johns Hopkins University

Justin Brantley

David R. Bangsberg · Center for Global Health

Jessica E. Haberer · Massachusetts General Hospital

Andrew Mujugira

Nelly Mugo

Abstract

Plasma concentrations of tenofovir consistent with daily dosing were highly predictive of protection from HIV acquisition. Most of those who took PrEP seemed to have high and consistent adherence.

Topics & Keywords

HIV/AIDS Research and Interventions HIV/AIDS drug development and treatment HIV Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAIDS Journal of Acquired Immune Deficiency Syndromes

Volume 66, Issue 3, pp. 340-348

DOI: 10.1097/qai.0000000000000172

Field-Weighted Citation Impact: 17.79